Recently Developed Neuroprotective Therapies for Acute Stroke

[1]  J. Harlan.  Neutrophil-mediated vascular injury. , 2009, Acta medica Scandinavica. Supplementum.

[2]  H. Rosing,et al.  Randomized trial of cervene, a κ receptor-selective opioid antagonist, in acute ischemic stroke* , 1996 .

[3]  T. Patel,et al.  Therapeutic Potential of Endothelin Receptor Antagonists in Cerebrovascular Disease , 1996 .

[4]  M Fisher,et al.  Medical therapy for ischemic stroke. , 1996, Clinical neuropharmacology.

[5]  B. Meldrum,et al.  Na+ channels as targets for neuroprotective drugs. , 1995, Trends in pharmacological sciences.

[6]  M Chopp,et al.  Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. , 1995, Stroke.

[7]  K. Lees,et al.  A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. , 1995, Stroke.

[8]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[9]  K. Lees,et al.  Clinical experience with excitatory amino acid antagonist drugs. , 1995, Stroke.

[10]  Douglas H. Smith,et al.  The Potential of 21-Aminosteroids (Lazaroids) as Neuroprotective Therapies in CNS Injury , 1995 .

[11]  J. Slattery,et al.  The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? , 1994, BMJ.

[12]  R. Porter,et al.  Anatomy and physiology of glutamate in the CNS , 1994, Neurology.

[13]  G. Rizzato,et al.  COMPARATIVE STUDY OF PROTIRELIN TARTRATE AND STANDARD THERAPY IN THE TREATMENT OF STROKE PATIENTS , 1994 .

[14]  K. Hossmann.  Viability thresholds and the penumbra of focal ischemia , 1994, Annals of neurology.

[15]  V. Mary,et al.  Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents , 1994, Neuroscience Letters.

[16]  N. Wahlgren,et al.  Intravenous Nimodipine West European Stroke Trial (INWEST) of Nimodipine in the Treatment of Acute Ischaemic Stroke , 1994 .

[17]  W. Ceusters,et al.  A double‐blind study of neurotropin in patients with acute ischemic stroke , 1994, Acta neurologica Scandinavica.

[18]  S. Fletcher,et al.  Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) , 1994, The Lancet.

[19]  G. Tognoni,et al.  From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders. , 1994, Clinical trials and meta-analysis.

[20]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[21]  F. Faraci,et al.  Nitric Oxide and the Cerebral Circulation , 1994, Stroke.

[22]  L. Wilkins.  Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). , 1994, Stroke.

[23]  K. Kogure,et al.  Altered Gene Expression in Cerebral Ischemia , 1993, Stroke.

[24]  D. Choi.  Nitric oxide: foe or friend to the injured brain? , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Mies,et al.  Correlation between peri-infarct DC shifts and ischaemic neuronal damage in rat. , 1993, Neuroreport.

[26]  Hugh S. Markus,et al.  Differentiation Between Different Pathological Cerebral Embolic Materials Using Transcranial Doppler in an In Vitro Model , 1993, Stroke.

[27]  B. Siesjö.  Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. , 1992, Journal of neurosurgery.

[28]  J. Mcculloch,et al.  Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. , 1992, British journal of clinical pharmacology.

[29]  S. Fletcher,et al.  Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) , 1992, The Lancet.

[30]  J. Belch.  Free Radicals and Their Scavenging in Stroke , 1992, Scottish Medical Journal.

[31]  N. Bornstein.  International Conference on Stroke. , 1992, Neurological Research.

[32]  G. Albers,et al.  Do NMDA antagonists prevent neuronal injury? Yes. , 1992, Archives of neurology.

[33]  A. Członkowska,et al.  A Double-Blind Controlled Trial of Naloxone in Early Treatment of Acute Ischemic Stroke , 1992 .

[34]  K Wienhard,et al.  Progressive Derangement of Periinfarct Viable Tissue in Ischemic Stroke , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  A. Cross,et al.  Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil , 1991, British journal of pharmacology.

[36]  A. Baker,et al.  Changes in Extracellular Concentrations of Glutamate, Aspartate, Glycine, Dopamine, Serotonin, and Dopamine Metabolites After Transient Global Ischemia in the Rabbit Brain , 1991, Journal of neurochemistry.

[37]  D. Choi,et al.  Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia. , 1991, Stroke.

[38]  P. Ell,et al.  99TCm-HMPAO SPECT studies in traumatic intracerebral haematoma. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[39]  F. Marcoux,et al.  Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. , 1990, Stroke.

[40]  M. Kocher.  Metabolic and hemodynamic activation of postischemic rat brain by cortical spreading depression. , 1990 .

[41]  D. Gambi,et al.  GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study--Hemodilution + Drug. , 1989, Stroke.

[42]  J. Bogousslavsky,et al.  A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. , 1989, Stroke.

[43]  G. Teasdale,et al.  Experimental intracerebral hemorrhage: progression of hemodynamic changes after production of a spontaneous mass lesion. , 1988, Neurosurgery.

[44]  D. Barer,et al.  Low dose β blockade in acute stroke (“BEST” trial): an evaluation , 1988 .

[45]  A. Członkowska,et al.  Effect of Naloxone on Acute Stroke , 1988, Pharmacopsychiatry.

[46]  M. Fujishima,et al.  Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. , 1988, Stroke.

[47]  W. Dalton Dietrich,et al.  Small Differences in Intraischemic Brain Temperature Critically Determine the Extent of Ischemic Neuronal Injury , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[48]  A. Guidotti,et al.  Ganglioside inhibition of glutamate-mediated protein kinase C translocation in primary cultures of cerebellar neurons. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Olney,et al.  Glutamate and the pathophysiology of hypoxic–ischemic brain damage , 1986, Annals of neurology.

[50]  H. Benveniste,et al.  Elevation of the Extracellular Concentrations of Glutamate and Aspartate in Rat Hippocampus During Transient Cerebral Ischemia Monitored by Intracerebral Microdialysis , 1984, Journal of neurochemistry.

[51]  M. Fisher,et al.  A Double Blind Trial of Naloxone in the Treatment of Acute Stroke , 1984, Stroke.

[52]  L. Symon,et al.  Extracellular pH, Potassium, and Calcium Activities in Progressive Ischaemia of Rat Cortex , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[53]  V. Moretti,et al.  DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF NALOXONE ON MOTOR DEFICITS IN ACUTE CEREBROVASCULAR DISEASE , 1984, The Lancet.

[54]  T Jones,et al.  Serial observations on the pathophysiology of acute stroke. The transition from ischaemia to infarction as reflected in regional oxygen extraction. , 1983, Brain : a journal of neurology.

[55]  B. Siesjö,et al.  Thresholds in cerebral ischemia - the ischemic penumbra. , 1981, Stroke.

[56]  W. Fitch.  Protection of the brain from ischaemia. , 1981, British journal of anaesthesia.

[57]  K. Hossmann,et al.  Experimental Brain Infarcts in Cats: I. Pathophysiological Observations , 1980, Stroke.

[58]  L. Sokoloff,et al.  Cerebral glucose utilization: local changes during and after recovery from spreading cortical depression. , 1979, Science.

[59]  A. Admani.  New approach to treatment of recent stroke. , 1978, British medical journal.

[60]  F. Sardella,et al.  Is There a Real Treatment for Stroke? Clinical and Statistical Comparison of Different Treatments in 300 Patients , 1978, Stroke.

[61]  V. Carstairs,et al.  The handicapped and impaired in Great Britain. , 1972, Health bulletin.

[62]  G. Lees.  Therapeutic Potential of AMPA Receptor Ligands in Neurological Disorders , 1996 .

[63]  M. Hennerici,et al.  Meta-Analysis of Oral Nimodipine Trials in Acute Ischemic Stroke , 1994 .

[64]  K. Herholz,et al.  Positron emission tomography imaging and the therapeutic window. , 1993, Stroke.

[65]  N. Qizilbash,et al.  Meta-Analysis of Trials of Glycerol in Acute Stroke , 1993 .

[66]  N. Qizilbash,et al.  Meta-Analysis of Trials of Corticosteroids in Acute Stroke , 1993 .

[67]  A. Guidotti.  Neurotoxicity of excitatory amino acids , 1990 .

[68]  M. Limburg,et al.  Flunarizine in acute ischemic stroke: a pilot study. , 1990, European neurology.

[69]  M. Blombäck,et al.  Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. , 1990, Stroke.

[70]  D. Wiebers,et al.  Animal models of stroke: are they relevant to human disease? , 1990, Stroke.

[71]  K. Herholz,et al.  Clinical efficacy of positron emission tomography , 1987, Developments in Nuclear Medicine.

[72]  Stephen J. Smith,et al.  NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones , 1986, Nature.

[73]  G. Araki,et al.  Clinical evaluation of GABA in the treatment of cerebrovascular disorders. Multi-center double-blind study in comparison with pyrithioxine and placebo. , 1981, Arzneimittel-Forschung.

[74]  P. Mcgeer,et al.  Kainic acid as a tool in neurobiology , 1978 .